| abstract |
A compound of formula (I): ** Formula ** or a pharmaceutically acceptable salt, solvate or stereoisomer thereof, for use in a method of treatment, control or prevention of a cancer of the blood or bone marrow, in where: R1 is: hydrogen; halo; - (CH2) nOH; (C1-C6) alkyl, optionally substituted with one or more halo; (C1-C6) alkoxy, optionally substituted with one or more halo; or - (CH2) nNHRa, where Ra is: hydrogen; (C1-C6) alkyl, optionally substituted with one or more halo; - (CH2) n- (aryl of 6 to 10 members); -C (O) - (CH2) n- (6 to 10-membered aryl) or -C (O) - (CH2) n- (6 to 10-membered heteroaryl), wherein the aryl or heteroaryl is optionally substituted with one or more of: halo; -SCF3; (C1-C6) alkyl, the same optionally substituted with one or more halo; or (C1-C6) alkoxy, the same optionally substituted with one or more halo; -C (O) -C1-C8 alkyl, wherein the alkyl is optionally substituted with one or more halo; -C (O) - (CH2) n- (C3-C10 cycloalkyl); -C (O) - (CH2) n-NRbRc, where Rb and Rc are each independently: hydrogen; (C1-C6) alkyl, optionally substituted with one or more halo; (C1-C6) alkoxy, optionally substituted with one or more halo; or aryl of 6 to 10 members, optionally substituted with one or more of: halo; (C1-C6) alkyl, the same optionally substituted with one or more halo; or (C1-C6) alkoxy, the same optionally substituted with one or more halo; -C (O) - (CH2) n-O-(C1-C6) alkyl; or -C (O) - (CH2) n-O- (CH2) n- (aryl of 6 to 10 members); R2 is: hydrogen; - (CH2) nOH; phenyl; -O-C1-C6 alkyl; or (C1-C6) alkyl, optionally substituted with one or more halo; R3 is: hydrogen; or (C1-C6) alkyl, optionally substituted with one or more halo; and n is 0, 1 or 2. |